Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.46 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PTPRC | P08575 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18430485 | 0.82 | NPC1 (0.51) | MAPTGAANPSR1POLBKMT2A | |
| SCHEMBL18499649 | 0.80 | MAPT (0.50) | MAPTGAANPSR1KMT2AMEN1 | |
| SCHEMBL28371251 | 0.80 | GAA (0.43) | MAPTGAANPSR1POLBKMT2A | |
| SCHEMBL20261868 | 0.79 | MAPT (0.60) | MAPTGAANPSR1KMT2AMEN1 | |
| SCHEMBL9005060 | 0.78 | GAA (0.49) | MAPTGAANPSR1KMT2APTPRC | |
| SCHEMBL713292 | 0.78 | GAA (0.49) | MAPTGAANPSR1KMT2APTPRC | |
| SCHEMBL6467711 | 0.77 | CYP3A4 (0.50) | MAPTGAANPSR1POLBKMT2A | |
| SCHEMBL3057004 | 0.77 | GAA (0.48) | MAPTGAANPSR1KMT2AALDH1A1 | |
| SCHEMBL18430409 | 0.76 | ALOX5 (0.60) | MAPTGAAKMT2AMEN1ALDH1A1 | |
| SCHEMBL6257110 | 0.76 | MAPT (0.42) | MAPTGAANPSR1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243188-A1 | METHIONINE ADENOSYLTRANSERASE 2A INHIBITORS | IDEAYA BIOSCIENCES, INC. | 2025-07-31 | — | — | US | disclosed |
| WO-2023196985-A1 | METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196985-A1 | METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-10655091-B2 | Thiophene azo dyes and laundry care compositions containing the same | THE PROCTER & GAMBLE COMPANY (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190345415-A1 | THIOPHENE AZO DYES AND LAUNDRY CARE COMPOSITIONS CONTAINING THE SAME | PROCTER & GAMBLE (US) | 2019-11-14 | — | — | US | disclosed |
| US-10435651-B2 | Thiophene azo dyes and laundry care compositions containing the same | THE PROCTER & GAMBLE COMPANY (US) | 2019-10-08 | — | — | US | disclosed |
| US-20180066215-A1 | THIOPHENE AZO DYES AND LAUNDRY CARE COMPOSITIONS CONTAINING THE SAME | PROCTER & GAMBLE (US) | 2018-03-08 | — | — | US | disclosed |
| US-9752104-B2 | Thiophene AZO carboxylate dyes and laundry care compositions containing the same | THE PROCTER & GAMBLE COMPANY (US) | 2017-09-05 | — | — | US | disclosed |
| US-9567465-B2 | Thiophene azo carboxylate dyes and laundry care compositions containing the same | MILLIKEN & COMPANY (US) | 2017-02-14 | — | — | US | disclosed |
| US-9556337-B2 | Thiophene azo dyes and laundry care compositions containing the same | MILLIKEN & COMPANY (US) | 2017-01-31 | — | — | US | disclosed |
| WO-2009017701-A2 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION (US) | 2009-02-05 | — | — | WO | disclosed |
| EP-1888063-B1 | ANTIFUNGAL AGENTS | F2G LTD (GB) | 2009-01-14 | — | — | EP | disclosed |
| WO-2008156614-A2 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080161302-A1 | N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus | F2G LTD. (GB) | 2008-07-03 | — | — | US | disclosed |
| EP-1888063-A1 | ANTIFUNGAL AGENTS | F2G Ltd. (GB) | 2008-02-20 | — | — | EP | disclosed |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| WO-2006123145-A1 | ANTIFUNGAL AGENTS | F2G LTD (GB) | 2006-11-23 | — | — | WO | disclosed |
| EP-1657238-A1 | FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-17 | — | — | EP | disclosed |
| US-5721248-A | CALCIUM AGONISTS; TREATING CARDIOVASCULAR DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 1998-02-24 | — | — | US | disclosed |
| US-5545646-A | CARDIOVASCULAR DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 1996-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243188-A1 | METHIONINE ADENOSYLTRANSERASE 2A INHIBITORS | MAT2A, MAT2B, MAT1A | MAPT 1876/4885GAA 1243/4885NPSR1 4092/4885 |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | NR5A1, GNRHR, RXFP3 | MAPT 4777/4885GAA 3884/4885NPSR1 69/4885 |
| US-20080161302-A1 | N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus | NAT1, CYP1A2, CYP51A1 | MAPT 2792/4885GAA 705/4885NPSR1 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.